Marked variability observed in inpatient management of bronchiolitis in three Finnish hospitals

Varpu Elenius (varpu.elenius@utu.fi), Eija Bergroth, Petri Koponen, Sami Remes, Pedro A. Piedra, Janice A. Espinola, Matti Korppi, Carlos A. Camargo Jr, Tuomas Jartti

1.Department of Paediatrics and Adolescent Medicine, Turku University Hospital, Turku, Finland
2.Department of Paediatrics, Kuopio University Hospital, Kuopio, Finland
3.Department of Paediatrics, Tampere University Hospital, Tampere, Finland
4.Departments of Molecular Virology and Microbiology and Pediatrics, Baylor College of Medicine, Houston, TX, USA
5.Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Keywords
Bronchiolitis guidelines, Bronchiolitis treatment, History of wheezing, Hospitalised infants, Practice variations

Correspondence
Dr V Elenius, Department of Paediatrics and Adolescent Medicine, Turku University Hospital, P.O. Box 52, 20520 Turku, Finland. Tel: +358 2 313 0700 | Fax: +358 2 313 1460 | Email: varpu.elenius@utu.fi

Received 22 March 2017; revised 26 April 2017; accepted 17 May 2017.

DOI: 10.1111/apa.13931

ABSTRACT
Aim: Infants hospitalised for bronchiolitis undergo examinations and treatments not supported by current research evidence and we investigated practice variations with regard to Finnish children under the age of two.

Methods: This prospective, multicentre cohort study was conducted in paediatric units in three university hospitals in Finland from 2008 to 2010. Hospital medical records were reviewed to collect data on clinical course, testing and treatment. Data were analysed separately for children meeting our strict definition of bronchiolitis, aged under 12 months without a history of wheezing, and a loose definition, aged 12–23 months or with a history of wheezing.

Results: The median age of the 408 children was 8.1 months. Clinical management varied between the three hospitals when stratified by strict and loose bronchiolitis subgroup definitions: complete blood counts ranged from 15–95% vs 16–94%, respectively, and the other measures were chest x-ray (16–91% vs 14–72%), intravenous fluids (2–47% vs 2–41%), use of nebulised epinephrine (10–84% vs 7–50%), use of salbutamol (18–21% vs 13–84%) and use of corticosteroids (6–23% vs 60–76%).

Conclusion: The clinical management of bronchiolitis varied considerably with regard to the three hospitals and the two definitions of bronchiolitis. A stronger commitment to evidence-based bronchiolitis guidelines is needed in Finland.

INTRODUCTION
Bronchiolitis is a lower respiratory tract viral infection in young children. Most European countries limit the diagnosis of bronchiolitis to infants age 12 months or younger and typically do not include those with a previous history of wheezing, whereas the USA uses an older age limit of less than 24 months (1). Bronchiolitis is one of the most common and costly respiratory illnesses in infants and young children (2). Approximately, 100 000 bronchiolitis admissions occur annually in the USA at an estimated cost of $1.7 billion (3). In Finland, up to 3% of infants with bronchiolitis under 12 months of age are hospitalised, and up to 9% require intensive care (4). In Finland, the mean hospitalisation cost for a bronchiolitis patient is €1800 and this figure goes up to €8000 if paediatric intensive care is needed (4).

Several randomised controlled trials and systematic reviews have attempted to identify the optimal treatments for children with bronchiolitis (5–8). Evidence-based care

Key Notes
- Many infants hospitalised for bronchiolitis undergo examinations and treatments not supported by current research evidence.
- We found that the clinical management of bronchiolitis varied considerably between three Finnish hospitals, based on 408 infants treated from 2008–2010, and whether they used the strict or loose definitions of bronchiolitis.
- A stronger commitment to evidence-based bronchiolitis guidelines is needed and future guidelines should make a distinction between these two definitions of bronchiolitis.
remains largely supportive, including adequate oxygenation, mucus extraction and nutrition. Despite international guidelines on bronchiolitis, the overuse of diagnostic testing, namely chest radiography and laboratory testing, and ineffective therapy, namely beta agonists, antibiotics and corticosteroids, remain common. The main reason for the overuse of testing and medication is the modest effectiveness of bronchiolitis guidelines in modifying physician behaviour (9–11).

In response to these problems, many hospitals have implemented clinical practice guidelines and recommendations based on evidence-based guidelines for bronchiolitis (12). These guidelines seldom recommend specific interventions and instead they try to prevent the use of irrelevant diagnostic tests or ineffective drug treatments or other interventions. Despite the high frequency and cost of bronchiolitis care, there has been limited research on the variability of care between different hospitals (9,13,14). Therefore, our aim was to investigate bronchiolitis-related practice variations in three tertiary care university hospitals in Finland. Due to the expected variability in the diagnostic and management practices, we wanted to investigate practice variation in two subgroups of children who were less than two years of age when they were hospitalised for bronchiolitis. The first subgroup was those who met our strict definition of bronchiolitis, as they were aged under 12 months of age without a history of wheezing and the second subgroup was those who did not meet our strict definition as they were 12–23 months of age or had a history of wheezing.

**METHODS**

**Subjects**

This prospective, multicentre cohort study was conducted as part of the Multicenter Airway Research Collaboration, a programme of the Emergency Medicine Network, during two consecutive winter seasons from November to March in the years 2008–2010. The study was carried on in the paediatric departments of three Finnish tertiary care university hospitals in Turku, Tampere and Kuopio, Finland (15). As in its USA counterpart study (16), a standardised protocol was used to enrol a target number of consecutive patients from the inpatient ward and the intensive care unit. Inclusion criteria were an attending physician’s diagnosis of bronchiolitis, age under two years and informed consent from a guardian. Patients were enrolled within 18 hours of admission. The exclusion criteria were previous enrolment or transfer to a participating hospital more than 48 hours after the original admission time. All patients were treated at the discretion of the treating physician. The institutional review board of Turku University Hospital approved the study, and this approval covered all participating hospitals in Finland.

**Data collection**

Investigators conducted a standardised structured interview on patients’ demographic, environmental and clinical characteristics (17). Patients were evaluated daily in the ward by a physician. Hospital medical records were used to collect clinical data from the pre-admission evaluation in the emergency department as well as the child’s inpatient course. These data were manually reviewed at the Emergency Medicine Network Coordinating Center and site investigators were queried about missing or discrepant data.

To evaluate bronchiolitis severity, a modified Respiratory Distress Severity Score (RDSS) was calculated based on four assessments made during the pre-admission visit: respiratory rate by age, presence of wheezing (yes or no), air entry (normal, mild difficulty or moderate to severe difficulty), and retractions (none, mild or moderate to severe) (15,18). Each component was assigned a score of zero, one or two, with the exception of wheezing, which was assigned either zero (no wheezing) or two (wheezing), and then summed for a possible total score of zero to eight per patient. When a child had one or two of the RDSS components missing (n = 174), single imputation controlling for age, respiratory rate, presence of wheezing, air entry and retractions, was used to generate the score. RDSS values were not calculated for the 15 patients missing data for more than two components of the score.

**Nasopharyngeal aspirate collection and viral testing**

Nasopharyngeal aspirates were collected at study entry using a standardised protocol (19). The sample was added to transport medium, immediately placed on ice, and then stored at −80°C before analysis at Baylor College of Medicine. All polymerase chain reaction (PCR) assays were conducted as singleplex or duplex two-step real-time PCR and used for the detection of RNA respiratory viruses; respiratory syncytial virus (RSV) types A and B, rhinovirus (RV) covering A, B and C species, parainfluenza virus types 1, 2 and 3, influenza virus types A, B and 2009 novel H1N1, human metapneumovirus, coronaviruses NL-63, HKU1, OC43 and 229E, enteroviruses and DNA pathogens for adenovirus. Details of the methods and primers and probes have been described previously (20,21).

**Statistical analyses**

All analyses were performed using Stata 14.1 (StataCorp LLC, College Station, TX, USA). Data are presented as proportions and means with 95% confidence intervals (95% CIs) or medians with interquartile ranges (IQRs). For analytical purposes, we divided the cohort into two subgroups by bronchiolitis definition: children under 12.0 months of age with no history of wheezing (strict bronchiolitis) or all other children in the cohort who were 12.0–23.9 months of age or had a history of wheezing (loose bronchiolitis).

To assess variability in care by study site, bivariate associations were tested using chi-square, and Fisher’s exact test, and Kruskal–Wallis test, as appropriate. To evaluate the effect of patient characteristics on practice variation between study sites, we created two multilevel mixed-effects logistic regression models for each test and treatment of interest and then calculated each model’s corresponding intraclass correlation coefficient (ICC). The
first model accounted for random site effects but did not adjust for patient-level characteristics. The second, more complete model specified random site effects while simultaneously adjusting for patient-level characteristics, that is, age, sex, insurance provider, major relevant comorbid disorder and RDSS. Therefore, the ICCs derived from our models that specify only random site effects represent the proportion of the total outcome variation that is attributable to site-level differences without adjusting for patient-level characteristics. The ICCs from our complete models represent the total outcome variation that is attributable to site-level differences after accounting for differences in patient-level characteristics.

All p values were two-tailed, with $p < 0.05$ considered statistically significant.

### RESULTS

**Study cohort and patient characteristics**

Altogether, 408 hospitalised children with bronchiolitis were enrolled (Table 1). Site A enrolled 135 patients, Site B 135 and Site C 138 patients. The median travel distances between home and hospital were 13 km for Site A, 47 km for Site B, and 21 km for Site C ($p < 0.001$). Among all children hospitalised for bronchiolitis, the median age was 8.1 months (IQR 3.3–14.8), they were more often male (62%), 24% had parents with asthma, and 37% had history of previous wheezing. Additionally, 13% were premature and 12% had major relevant comorbid disorder. Virology testing revealed that 43% were RSV positive and 32% were RV positive, both with and without other detected viruses.

Table 1 Characteristics of hospitalised bronchiolitis patients by bronchiolitis definition (n = 408)

| Characteristics                      | All subjects (n=408) | Strict bronchiolitis (n=206) | Loose bronchiolitis (n=202) | p   |
|--------------------------------------|---------------------|-----------------------------|----------------------------|------|
|                                      | n       | %    | n       | %    | n       | %    |       |
| A                                    | 135     | 33   | 91      | 44   | 44      | 22   | <0.001|
| B                                    | 135     | 33   | 64      | 31   | 71      | 35   |       |
| C                                    | 138     | 34   | 51      | 25   | 87      | 43   |       |
| Distance between home and site, km (median, IQR) | 402    | 19 (9–53) | 205    | 22 (8–57) | 197 | 17 (9–45)   | 0.47 |
| Age in months (median, IQR)          | 408     | 8.1 (3.3–14.8) | 206   | 3.7 (1.8–6.6) | 202 | 14.8 (10.8–18.3) | <0.001 |
| Age in months                        |         |      |         |      |         |      |       |
| <1 month                             | 23      | 6    | 23      | 11   | 0       | 0    | <0.001|
| 1–1.9                                | 41      | 10   | 36      | 17   | 5       | 2    |       |
| 2–3.9                                | 62      | 15   | 52      | 25   | 10      | 5    |       |
| 4–5.9                                | 43      | 11   | 36      | 17   | 7       | 3    |       |
| 6–11.9                               | 95      | 23   | 59      | 29   | 36      | 18   |       |
| ≥12                                  | 144     | 35   | 0       | 0    | 144     | 71   |       |
| Sex                                  |         |      |         |      |         |      |       |
| Male                                 | 251     | 62   | 119     | 58   | 132     | 65   | 0.12  |
| Female                               | 157     | 38   | 87      | 42   | 70      | 35   |       |
| Race                                 |         |      |         |      |         |      |       |
| White                                | 403     | 99   | 208     | 99   | 200     | 99   | 0.85  |
| Black                                | 3       | 1    | 2       | 1    | 1       | 0.5  |       |
| Other or Missing                     | 2       | 0    | 0       | 0.5  | 1       | 0.5  |       |
| RDSS, quartiles                      |         |      |         |      |         |      |       |
| 1 (0–3.05)                           | 99      | 24   | 65      | 32   | 34      | 17   | <0.001|
| 2 (3.12–5.00)                        | 112     | 27   | 71      | 34   | 41      | 20   |       |
| 3 (5.003–6.41)                       | 84      | 21   | 35      | 17   | 49      | 24   |       |
| 4 (6.44–8.0)                         | 98      | 24   | 30      | 15   | 68      | 34   |       |
| Missing                              | 15      | 4    | 5       | 2    | 10      | 5    |       |
| Inpatient                            |         |      |         |      |         |      |       |
| ICU                                  | 13      | 3    | 13      | 6    | 0       | 0    | <0.001|
| Hospital LOS (days), median (IQR)    | 408     | 2 (1–3) | 206    | 2 (1–3) | 202 | 1.5 (1–3) | 0.07 |
| Hospital ≥3 LOS (days)               | 130     | 32   | 73      | 35   | 57      | 28   | 0.12  |
| Virology                             |         |      |         |      |         |      |       |
| RSV                                  | 175     | 43   | 133     | 65   | 42      | 21   | <0.001|
| RV                                   | 130     | 32   | 29      | 14   | 101     | 50   | <0.001|
| Number of infections                 |         |      |         |      |         |      |       |
| 0                                    | 58      | 14   | 24      | 12   | 34      | 17   | 0.33  |
| 1                                    | 287     | 70   | 149     | 72   | 138     | 68   |       |
| ≥2                                   | 63      | 15   | 33      | 16   | 30      | 15   |       |

IQR, interquartile range; RDSS, respiratory distress severity score; ICU, intensive care unit; LOS, length of stay; RSV respiratory syncytial virus; RV, rhinovirus.
Of all children, 206 (50%) children met our strict definition of bronchiolitis while 202 met the loose definition. Children with strict bronchiolitis were younger partly due to definition, had generally lower RDSS score although exclusively included intensive care unit patients, had RSV more often, and rhinovirus less often (all \( p < 0.001 \); Table 1).

**Patient characteristics by site**

Overall, patient characteristics did not differ by site for sex, race, prematurity or parental history of asthma. However, median age of patients and comorbidity varied between sites: at Site A the median age of patients was 6.0 months, at Site B it was 8.1 months and at Site C it was 10.4 months (\( p < 0.001 \)). Comorbidity was highest 17% at Site A, it was 13% at Site B and only 6% at Site C (\( p = 0.01 \)). Also, RDSS varied significantly by site: the mean RDSS was highest 5.5 at Site A, it was 5.1 at Site C and 4.0 at Site B (\( p < 0.001 \)). Taken together, Site A treated younger, more severely ill patients with highest proportion of comorbid disorders.

**Testing and medical interventions by site, stratified by bronchiolitis definition**

Diagnostic testing differed significantly between the hospital sites (Fig. 1). Among children with strict bronchiolitis (Fig. 1A), complete blood count (CBC) and chest x-ray were performed for nearly all patients at Site B (95% and 91%, respectively), and only few patients at Site A (15% and 18%, respectively) (both \( p < 0.001 \)). At Site C, CBC was performed from 61% and chest x-ray from 16% of patients with strict bronchiolitis. Intravenous fluids were given to 47% of patients at Site B, and 8% and 2% of patients at Site A and C (\( p < 0.001 \)).

Among children with loose bronchiolitis (Fig. 1B), the amount of diagnostic testing remained high at Site B (CBC 94%, chest x-ray 72%), and remained low at Site A (16%, and 14%, respectively), and C (60% and 20%, respectively) (both \( p < 0.001 \)). Also, the difference in giving intravenous fluids between hospitals varied. Intravenous fluids were given to 41% of patients at Site B, and 2% and 7% of patients at Site A and C (\( p < 0.001 \)).

**Medical treatments by site, stratified by bronchiolitis definition**

There were also marked differences in medical treatments between the sites (Fig. 2). Among children with strict bronchiolitis (Fig. 2A), the use of nebulised epinephrine was lowest at Site A (10%), highest at Site B (84%), and intermediate at Site C (49%) (\( p < 0.001 \)). No difference between sites was found in the use of salbutamol (\( p = 0.95 \)), nor in the use of antibiotics (\( p = 0.21 \)). Use of corticosteroids was 6% at Site A, 8% at Site B, and 23% at Site C (\( p = 0.03 \)).

Among children with loose bronchiolitis (Fig. 2B), the use of bronchodilators differed between the study sites. The use of nebulised epinephrine was 8% at Site A, 50% at Site B, and 7% at Site C (\( p < 0.001 \)). The use of salbutamol was 84% at Site A, 78% at Site B, and 13% at Site C (\( p < 0.001 \)). No difference between sites was found in the use of antibiotics (\( p = 0.13 \)), nor in the use of corticosteroids (\( p = 0.26 \)).

**Intersite variability with adjustment for patient characteristics**

To evaluate the effect of patient characteristics on care variability between study sites, we calculated ICCs from mixed-effects logistic regression models (Table 2). Overall, comparing the ICCs from models that excluded patient characteristics (Model A) and the ICCs from models that adjusted for patient demographic and clinical
characteristics (Model B), the site-attributable variability remained relatively consistent for each outcome after adjustment.

In the strict bronchiolitis subgroup, salbutamol and inpatient antibiotic use exhibited the lowest percentages of site-attributable variability (all ICCs <1%), while performance of CBC, chest x-ray, intravenous fluids, and use of epinephrine demonstrated the highest percentages of variability (all ICCs >40%).

In the loose bronchiolitis subgroup, use of corticosteroids and antibiotics demonstrated the lowest percentages of site-attributable variability (all ICCs <5%), while CBC performed and use of salbutamol demonstrated the highest percentages of variability (all ICCs >40%).
DISCUSSION
We found that use of diagnostic tests and treatment varied considerably between three Finnish hospitals whether a strict or loose definitions of bronchiolitis was used. Variability was not explained by the differences in patient demographics or clinical characteristics. Excessive diagnostic testing and treatments of bronchiolitis may have adverse effects and will certainly increase costs. Therefore, the latest 2014 American Academy of Pediatrics, 2015 National Institute for Health and Care Excellence and 2016 Finnish bronchiolitis guidelines recommend the supportive care of bronchiolitis with adequate oxygenation and nutrition (12,22,23). Our study was performed during 2008–2010, before publication of these latest guidelines, which may explain some of the excessive testing and treatments observed.

Considering diagnostics of bronchiolitis, we found that use of CBC and chest radiography was more common in both clinical subgroups at Site B, although the patients presented with a comparatively less severe illness. According to guidelines, clinicians should diagnose bronchiolitis and assess disease severity on the basis of history and physical examination and radiographic or laboratory studies should not be obtained routinely (12,22,23). However, clinicians should assess risk factors for severe disease, such as age less than 12 weeks, a history of prematurity, underlying cardiopulmonary disease, or immunodeficiency, when making decisions about evaluation and management of children with bronchiolitis. We speculate that the long travel distances between home and hospital at Site B might explain some of these results. If the distance between home and hospital is long, the pressure to perform diagnostic tests and give treatments before discharge might be higher.

In the treatment of bronchiolitis, the largest site differences were found in the use of epinephrine among children with strict definition of bronchiolitis, and in the use of epinephrine and salbutamol among those with loose definition of bronchiolitis. On the contrary, the variability of corticosteroid use was rather low, but it was used quite often among children with loose definition of bronchiolitis. Use of nebulised epinephrine in bronchiolitis patients less than 12 months was national practice in Finland before new randomised trials were published (24–26). This practice was also seen in the study comparing Finnish and Swedish bronchiolitis treatment practices (14). According to recent guidelines, beta agonists and corticosteroids are the most commonly overused, nonevidence-based therapies (12,22,23). Several studies and reviews have evaluated the use of bronchodilators for bronchiolitis patients under two years old, but most randomised controlled trials have failed to demonstrate a consistent benefit (6). The same is true for use of corticosteroids (8,27). The major limitation of these earlier studies was that a subgroup of high asthma risk children was not evaluated separately (20,21). However, much of the continued use of bronchodilators and corticosteroids may arise from similarities in the signs and symptoms between bronchiolitis and asthma, especially with those children close to age two years having risk factors for asthma or recurrent wheezing (28,29). It is not surprising that clinician chooses to try beta agonists for these older children with asthma risk factors. Most likely, a 23-month-old child with RV infection and a history of wheezing has a different kind of disease than a three-month-old infant with RSV. As the current guidelines do not separate these two subgroups, it might be that what is true for the treatment of strict definition of bronchiolitis is not necessarily true for treatment of loose definition of bronchiolitis.

Of other treatments, use of intravenous fluids varied greatly in both bronchiolitis subgroups, with Site B preferring intravenous fluids more than the other sites. We speculate that the other sites more often used nasogastric tube for hydration, but these data were not collected in our study. Guidelines do not prefer either hydration methods, but nasogastric tube can be considered more physiological, and easier to implement, although it may trap mucus and prolong wheezing. Variability in the use for antibiotics was low. The strengths of our study included a multiyear, multicentre cohort of severely ill bronchiolitis patients, with adjustment for demographic and clinical factors. We evaluated several clinical factors that might have influenced clinical decision-making including parent history of asthma, history of previous wheezing, RDSS, fever and comorbid conditions, but these factors did not explain the variability of practice. Our cohort represented severe bronchiolitis cases because all were admitted to hospital. Therefore, ideally, there should have been less observed site variability in tests and treatments. In this paper, we show that even after adjusting for demographic and clinical factors, wide variations between hospitals persisted. Furthermore, wide variation in practice was seen between strict and loose bronchiolitis subgroups. However, this study was not designed to determine the causes for the practice variation; reasons for testing and treatment were not queried. Also, the study was performed before publication of the current guidelines, so we do not know how well the latest guidelines are followed. The follow-up studies are currently ongoing.

CONCLUSION
We observed marked differences in diagnostic testing and treatments for bronchiolitis both in children with strict or loose definitions of bronchiolitis. Many infants hospitalised for bronchiolitis undergo examinations and treatments not supported by current research evidence or guidelines for bronchiolitis. These results call for stronger commitment to the evidence-based bronchiolitis guidelines (12,22,23).

ACKNOWLEDGEMENTS
We thank Ashley F Sullivan, MS, MPH (Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA) for coordinating the Multicenter Airways Research Collaboration in Finland study.
FINANCE
The Academy of Finland (grant numbers 114034, 132595 and 267133), the Finnish Medical Foundation and Tuberculosis Foundation of Tampere, all in Finland, supported this work.

CONFLICT OF INTEREST DISCLOSURES
None.

References
1. Meissner HC. Viral Bronchiolitis in Children. N Engl J Med 2016; 374: 62–72.
2. Carroll KN, Gebretsadik T, Griffin MR, Wu P, Dupont WD, Mitchell EF, et al. Increasing burden and risk factors for bronchiolitis-related medical visits in infants enrolled in a state health care insurance plan. Pediatrics 2008; 122: 58–64.
3. Hasegawa K, Tsugawa Y, Brown DF, Mansbach JM, Camargo CA. Temporal trends in emergency department visits for bronchiolitis in the United States, 2006 to 2010. Pediatr Infect Dis J 2014; 33: 11–8.
4. Heikilä P, Forma L, Korppi M. Hospitalisation costs for infant bronchiolitis are up to 20 times higher if intensive care is needed. Acta Paediatr 2015; 104: 269–73.
5. Schroeder AR, Mansbach JM. Recent evidence on the management of bronchiolitis. Curr Opin Pediatr 2014; 26: 328–33.
6. Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev 2014; 6: CD001266.
7. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev 2013; 7: CD006458.
8. Fernandes RM, Hartling L. Glucocorticoids for acute viral bronchiolitis in infants and young children. JAMA 2014; 311: 87–8.
9. Ralston S, Comick A, Nichols E, Parker D, Lanter P. Effectiveness of quality improvement in hospitalization for bronchiolitis: a systematic review. Pediatrics 2014; 134: 571–81.
10. Parikh K, Hall M, Teach SJ. Bronchiolitis management before and after the AAP guidelines. Pediatrics 2014; 133: e1–7.
11. McCulloh RJ, Smitherman SE, Koehn KL, Alverson BK. Assessing the impact of national guidelines on the management of children hospitalized for acute bronchiolitis. Pediatr Pulmonol 2014; 49: 688–94.
12. Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics 2014; 134: e1474–502.
13. Florin TA, Byczkowski T, Ruddy RM, Zorc JJ, Test M, Shah SS. Variation in the management of infants hospitalized for bronchiolitis persists after the 2006 American Academy of Pediatrics bronchiolitis guidelines. J Pediatr 2014; 165: 786–92.
14. Mecklin M, Hesselmar B, Qvist E, Wennergren G, Korppi M. Diagnosis and treatment of bronchiolitis in Finnish and Swedish children’s hospitals. Acta Paediatr 2014; 103: 946–50.
15. Jartti T, Aakula M, Mansbach JM, Piedra PA, Bergroth E, Koponen P, et al. Hospital length-of-stay is associated with rhinovirus etiology of bronchiolitis. Pediatr Infect Dis J 2014; 33: 829–34.
16. Macias CG, Mansbach JM, Fisher ES, Riederer M, Piedra PA, Sullivan AF, et al. Variability in inpatient management of children hospitalized with bronchiolitis. Acad Pediatr 2015; 15: 69–76.
17. Mansbach JM, Piedra PA, Stevenson MD, Sullivan AF, Forgey TF, Clark S, et al. Prospective multicenter study of children with bronchiolitis requiring mechanical ventilation. Pediatrics 2012; 130: e492–500.
18. Bajaj L, Turner CG, Bothner J. A randomized trial of home oxygen therapy from the emergency department for acute bronchiolitis. Pediatrics 2006; 117: 653–40.
19. Mansbach JM, McAdam AJ, Clark S, Hain PD, Flood RG, Acholonu U, et al. Prospective multicenter study of the viral etiology of bronchiolitis in the emergency department. Acad Emerg Med 2008; 15: 111–8.
20. Lukkarinen M, Lukkarinen H, Lehtinen P, Vuorinen T, Ruuskanen O, Jartti T. Prednisolone reduces recurrent wheezing after first rhinovirus wheeze: a 7-year follow-up. Pediatr Allergy Immunol 2013; 24: 237–43.
21. Jartti T, Nieminen R, Vuorinen T, Lehtinen P, Vahberg T, Gern J, et al. Short- and long-term efficacy of prednisolone for first acute rhinovirus-induced wheezing episode. J Allergy Clin Immunol 2015; 135: 691–8.
22. Tapiainen T, Aittoniemi J, Immonen J, Jylkkä H, Meinander T, Nuolivirta K, et al. Finnish guidelines for the treatment of laryngitis, wheezing bronchitis and bronchiolitis in children. Acta Paediatr 2016; 105: 44–9.
23. National Institute for Health and Care Excellence. Bronchiolitis: diagnosis and management of bronchiolitis in children. (Clinical guideline ng9.) 2015. Available at: www.nice.org.uk/guidance/ng9.
24. Skjerven HO, Hunderi JO, Brügmann-Pieper SK, Brun AC, Engen H, Eskedal L, et al. Racemic adrenaline and inhalation strategies in acute bronchiolitis. N Engl J Med 2013; 368: 2286–93.
25. Skjerven HO, Rolfsjord LB, Berents TL, Engen H, Dizdarevic E, Midgaard C, et al. Allergic diseases and the effect of inhaled epinephrine in children with acute bronchiolitis: follow-up from the randomised, controlled, double-blind, Bronchiolitis ALL trial. Lancet Respir Med 2015; 3: 702–8.
26. Zorc JJ. Inhaled epinephrine does not shorten hospital stay for infants with bronchiolitis destined to develop repeated bronchospasm. Lancet Respir Med 2015; 3: 665–7.
27. Fernandes RM, Bialy LM, Vandermeer B, Tjosvold L, Plint AC, Patel H, et al. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev 2013; 6: CD004878.
28. Guilbert TW, Morgan WJ, Zeiger RS, Bacharier LB, Boehmer SJ, Krawiec M, et al. Atopic characteristics of children with recurrent wheezing at high risk for the development of childhood asthma. J Allergy Clin Immunol 2004; 114: 1282–7.
29. Jartti T, Lehtinen P, Vuorinen T, Ruuskanen O. Bronchiolitis: age and previous wheezing episodes are linked to viral etiology and atopic characteristics. Pediatr Infect Dis J 2009; 28: 311–7.